Session 10: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit II
Chairs: Olivia Pagani (Switzerland), Sibylle Loibl (Germany)
- Emerging strategies in neoadjuvant treatment of patients with HER2 positive early breast cancer (Nadia Harbeck, Germany)
- Adjuvant treatment in patients with HER2 positive breast cancer: Risk stratification, type and duration (Ian Krop, USA)
- Neoadjuvant and adjuvant treatment of patients with TNBC (Javier Cortes, Spain)
- Breast cancer survivorship care beyond local and systemic therapy (Antonio C Wolff, USA)
BCC2019 PARTICIPANT: PASSWORD in BCC e-mail from March 23.